Rivaroxaban in patients with a recent acute coronary syndrome

ATLAS ACS 2–TIMI 51 Investigators, Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, Jean-Pierre Bassand, Deepak L Bhatt, Christoph Bode, Paul Burton, Marc Cohen, Nancy Cook-Bruns, Keith A A Fox, Shinya Goto, Sabina A Murphy, Alexei N Plotnikov, David Schneider, Xiang Sun, Freek W A Verheugt, C Michael Gibson

Research output: Contribution to journalArticlepeer-review

Abstract

Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.
Original languageEnglish
Pages (from-to)9-19
Number of pages11
JournalNew England Journal of Medicine
Volume366
Issue number1
DOIs
Publication statusPublished - 2012

Fingerprint

Dive into the research topics of 'Rivaroxaban in patients with a recent acute coronary syndrome'. Together they form a unique fingerprint.

Cite this